1. PICO Table.

E (Evidence)	One review included seven small randomised controlled trials comparing cholinesterase inhibitors with placebo which found no significant efficacy for improving cognitive function.
P (Population)	Patients with Hungtington's disease, CADASIL, multiple sclerosis, progressive supranuclear palsy, or frontotemporal dementia
	Suggesting large sample size (adequately powered studies able to show clinically relevant differences on patient relevant outcomes).
I (Intervention)	Currently marketed cholinesterase inhibitors
	Suggesting longer duration of intervention (more than 6 months) and long‐term (more than 12 months) to follow up.
C (Comparison)	Placebo
O (Outcome)	Suggesting common assessment of cognitive level (for example, ADCS‐CGIC score).
T (Time stamp)	June 2014
Study type	Randomised controlled trial
	Methods: concealment clear
	Blinding: patients, therapists, assessors blinded

ADCS‐CGIC = Alzheimer's Disease Cooperative Study‐Clinical Global Impression of Change